SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
SUMMARY The SRPK family of kinases regulates pre-mRNA splicing by phosphorylating serine/arginine (SR)-rich splicing factors, signals splicing control in response to extracellular stimuli, and contributes to tumorigenesis, suggesting that these splicing kinases are potential therapeutic targets. Here, we report the development of the first irreversible SRPK inhibitor, SRPKIN-1, which is also the first kinase inhibitor that forms a covalent bond with a tyrosine phenol group in the ATP-binding pocket. Kinome-wide profiling demonstrates its selectivity for SRPK1/2, and SRPKIN-1 attenuates SR protein phosphorylation at submicromolar concentrations. Vascular endothelial growth factor (VEGF) is a known target for SRPK-regulated splicing and, relative to the first-generation SRPK inhibitor SRPIN340 or small interfering RNA-mediated SRPK knockdown, SRPKIN-1 is more potent in converting the pro-angiogenic VEGF-A165a to the anti-angiogenic VEGF-A165b isoform and in blocking laser-induced neovascularization in a murine retinal model. These findings encourage further development of SRPK inhibitors for treatment of age-related macular degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
The Spliceosome: Design Principles of a Dynamic RNP Machine
Wahl, M. C., Will, C. L., & Lührmann, R. (2009) · Cell · doi:10.1016/j.cell.2009.02.009 · Cited by 2,665
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“…VEGF-blocking antibodies such as Ranibizumab has been successfully used for treating age-related macular degeneration (AMD) (Rosenfeld et al., 2006; Gragoudas et al., 2004), an intraocular neovascularization disease caused by abnormal growth of blood vessels inside the eye (Seddon and Chen, 2004).”
BackgroundThe resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · cited 2×
“Rationally designed covalent kinase inhibitors have recently experienced a resurgence of interest (Singh et al., 2011), and some have been approved by the FDA, including osimertinib and Ibrutinib for targeting mutant EGFR and BTK, respectively.”
BackgroundFinlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636 · cited 3×
“Following a successful strategy for improving the selectivity in the cases of Ibrutinib (Davids and Brown, 2014), AZD9291 (Finlay et al., 2014), and THZ1 (Kwiatkowski et al., 2014), we considered Cell Chemical Biology 25, 1–11, April 19, 2018 3 targeting Tyr227, which is located proximal to the morpholine group of Ale…”
BackgroundMethodBauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534 · cited 1×
“Covalent modification of a specific residue by covalent inhibitors can afford medicinal chemists the opportunity to gain greater selectivity, potency, and extended residence over reversible inhibitors (Singh et al., 2011; Bauer, 2015).”
BackgroundNakagawa, O., Arnold, M., Nakagawa, M., Hamada, H., Shelton, J. M., Kusano, H., Harris, T. M., Childs, G., Campbell, K. P., Richardson, J. A., et al. (2005) · Genes & Development · doi:10.1101/gad.1338705 · Cited by 125 · cited 1×
“The human genome encodes three SRPK genes, and SRPK1 has been detected in many human tissues, at varying levels of expression, while SRPK2 and SRPK3 exhibit tissue-specific expression in neurons and muscles, respectively (Wang et al., 1998; Nakagawa et al., 2005).”
Background
Cited by
Roles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S. C., López-Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 731
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Alternative splicing and cancer: a systematic review
Zhang, Y., Qian, J., Gu, C., & Yang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00486-7 · Cited by 497
Advances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
Metadata
- Authors
- Hatcher, J. M., Wu, G., Zeng, C., Zhu, J., Meng, F., Patel, S., Wang, W., Ficarro, S. B., Leggett, A. L., Powell, C. E., Marto, J. A., Zhang, K., Ki Ngo, J. C., Fu, X.-D., Zhang, T., & Gray, N. S.
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 25
- Issue
- 4
- Pages
- 460-470.e6
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- OpenAlex
- W2789218745
- Cited by
- 131
- References
- 7
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.